Showing 1 - 10 of 290
Between 1998 and 2004, Latvia achieved substantial progress in poverty reduction, with an estimated 325,000 people moving out of poverty over this period. This report examines the extent and causes of poverty reduction during this period using data from a variety of sources, the national...
Persistent link: https://www.econbiz.de/10012553156
The second Economic Update for Cabo Verde focuses on the importance of returning to fiscal sustainability in the aftermath of the COVID-19 crisis and on the potential role of Information and Communications Technology (ICT) in strengthening the foundations for a sustainable and inclusive economic...
Persistent link: https://www.econbiz.de/10013545358
Persistent link: https://www.econbiz.de/10011393507
This publication, which is based on the unique methodology and tools developed for the World Bank Institute/Harvard School of Public Health Flagship Course on Health System Reform and Sustainable Financing, provides a powerful set of resources to help policy makers better navigate the...
Persistent link: https://www.econbiz.de/10012550449
Persistent link: https://www.econbiz.de/10012245397
Compared with developed economies, health expenditure in China is not particularly high on a per capita basis or as a share of Gross Domestic Product (GDP). Similarly, pharmaceutical expenditure in comparative perspective is not particularly high on a per capita basis or as a percentage of GDP....
Persistent link: https://www.econbiz.de/10012247334
This paper examines the financing, pricing, and utilization of pharmaceuticals in China the pharmaceutical system as it has evolved, and some changes that would improve it in the context of the national health reform process. The present paper builds upon earlier critical reviews and other...
Persistent link: https://www.econbiz.de/10012247481
India for traditional platforms and high-volume production. Countries with domestic COVID-19 vaccine manufacturing capacity …
Persistent link: https://www.econbiz.de/10014578934
challenge, with manufacturing mostly concentrated in the US and Europe for high-value mRNA vaccines, and China and India for …
Persistent link: https://www.econbiz.de/10014579804